Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema

Glenn C Yiu, Varsha Manjunath, Stephanie J. Chiu, Sina Farsiu, Tamer H. Mahmoud

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

PURPOSE: To determine the effect of anti-vascular endothelial growth factor (VEGF) therapy on choroidal thickness in eyes with diabetic macular edema (DME). DESIGN: Aretrospective, cohort analysis of 59 eyes from 59 patients with DME without prior anti-VEGF therapy. METHODS: Choroidal thickness was measured using semiautomated segmentation of enhanced depth imaging optical coherence tomography images at 0.5-mm intervals from 2.5 mm nasal to 2.5 mm temporal to the fovea. Changes in choroidal thickness with and without anti- VEGF treatment over 6 months were compared. Bestcorrected visual acuity and central foveal thickness were analyzed to evaluate the association of choroidal thickness with functional and anatomic outcomes. RESULTS: Of the 59 eyes with DME, 26 eyes were observed without treatment, whereas 33 underwent intravitreal anti-VEGF therapy (mean number of injections, 2.73) over 6 months. In untreated eyes, there was no significant change in best-corrected visual acuity (P [ .098), central foveal thickness (P [ .472), or choroidal thickness at all measurements along the macula (P[ .057 at the fovea). In eyes treated with anti-VEGF injections, choroidal thickness decreased significantly at the fovea (246.6 to 224.8 mm; P < .001) and at 0.5 mm nasal (240.9 to 221.9 mm; P [ .002) and 0.5 mm temporal (249.3 to 224.8 mm; P [ .011) to the fovea. The decrease in subfoveal choroidal thickness after anti-VEGF treatment was not associated with the cumulative number of anti-VEGF injections (R2 [ 0.031; P [ .327) or to changes in best-corrected visual acuity (R2 [ 0.017; P [ .470) or central foveal thickness (R2 [ 0.040; P [ .263). CONCLUSIONS: Central choroidal thickness decreases after anti-VEGF therapy for DME after 6 months, but may not be associated with functional or anatomic outcomes in eyes with DME.

Original languageEnglish (US)
Pages (from-to)745-751.e2
JournalAmerican Journal of Ophthalmology
Volume158
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Macular Edema
Vascular Endothelial Growth Factor A
Visual Acuity
Therapeutics
Nose
Injections
Optical Coherence Tomography
Cohort Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema. / Yiu, Glenn C; Manjunath, Varsha; Chiu, Stephanie J.; Farsiu, Sina; Mahmoud, Tamer H.

In: American Journal of Ophthalmology, Vol. 158, No. 4, 2014, p. 745-751.e2.

Research output: Contribution to journalArticle

Yiu, Glenn C ; Manjunath, Varsha ; Chiu, Stephanie J. ; Farsiu, Sina ; Mahmoud, Tamer H. / Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema. In: American Journal of Ophthalmology. 2014 ; Vol. 158, No. 4. pp. 745-751.e2.
@article{9932364ed732409997bc4eb586f5f3f6,
title = "Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema",
abstract = "PURPOSE: To determine the effect of anti-vascular endothelial growth factor (VEGF) therapy on choroidal thickness in eyes with diabetic macular edema (DME). DESIGN: Aretrospective, cohort analysis of 59 eyes from 59 patients with DME without prior anti-VEGF therapy. METHODS: Choroidal thickness was measured using semiautomated segmentation of enhanced depth imaging optical coherence tomography images at 0.5-mm intervals from 2.5 mm nasal to 2.5 mm temporal to the fovea. Changes in choroidal thickness with and without anti- VEGF treatment over 6 months were compared. Bestcorrected visual acuity and central foveal thickness were analyzed to evaluate the association of choroidal thickness with functional and anatomic outcomes. RESULTS: Of the 59 eyes with DME, 26 eyes were observed without treatment, whereas 33 underwent intravitreal anti-VEGF therapy (mean number of injections, 2.73) over 6 months. In untreated eyes, there was no significant change in best-corrected visual acuity (P [ .098), central foveal thickness (P [ .472), or choroidal thickness at all measurements along the macula (P[ .057 at the fovea). In eyes treated with anti-VEGF injections, choroidal thickness decreased significantly at the fovea (246.6 to 224.8 mm; P < .001) and at 0.5 mm nasal (240.9 to 221.9 mm; P [ .002) and 0.5 mm temporal (249.3 to 224.8 mm; P [ .011) to the fovea. The decrease in subfoveal choroidal thickness after anti-VEGF treatment was not associated with the cumulative number of anti-VEGF injections (R2 [ 0.031; P [ .327) or to changes in best-corrected visual acuity (R2 [ 0.017; P [ .470) or central foveal thickness (R2 [ 0.040; P [ .263). CONCLUSIONS: Central choroidal thickness decreases after anti-VEGF therapy for DME after 6 months, but may not be associated with functional or anatomic outcomes in eyes with DME.",
author = "Yiu, {Glenn C} and Varsha Manjunath and Chiu, {Stephanie J.} and Sina Farsiu and Mahmoud, {Tamer H.}",
year = "2014",
doi = "10.1016/j.ajo.2014.06.006",
language = "English (US)",
volume = "158",
pages = "745--751.e2",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema

AU - Yiu, Glenn C

AU - Manjunath, Varsha

AU - Chiu, Stephanie J.

AU - Farsiu, Sina

AU - Mahmoud, Tamer H.

PY - 2014

Y1 - 2014

N2 - PURPOSE: To determine the effect of anti-vascular endothelial growth factor (VEGF) therapy on choroidal thickness in eyes with diabetic macular edema (DME). DESIGN: Aretrospective, cohort analysis of 59 eyes from 59 patients with DME without prior anti-VEGF therapy. METHODS: Choroidal thickness was measured using semiautomated segmentation of enhanced depth imaging optical coherence tomography images at 0.5-mm intervals from 2.5 mm nasal to 2.5 mm temporal to the fovea. Changes in choroidal thickness with and without anti- VEGF treatment over 6 months were compared. Bestcorrected visual acuity and central foveal thickness were analyzed to evaluate the association of choroidal thickness with functional and anatomic outcomes. RESULTS: Of the 59 eyes with DME, 26 eyes were observed without treatment, whereas 33 underwent intravitreal anti-VEGF therapy (mean number of injections, 2.73) over 6 months. In untreated eyes, there was no significant change in best-corrected visual acuity (P [ .098), central foveal thickness (P [ .472), or choroidal thickness at all measurements along the macula (P[ .057 at the fovea). In eyes treated with anti-VEGF injections, choroidal thickness decreased significantly at the fovea (246.6 to 224.8 mm; P < .001) and at 0.5 mm nasal (240.9 to 221.9 mm; P [ .002) and 0.5 mm temporal (249.3 to 224.8 mm; P [ .011) to the fovea. The decrease in subfoveal choroidal thickness after anti-VEGF treatment was not associated with the cumulative number of anti-VEGF injections (R2 [ 0.031; P [ .327) or to changes in best-corrected visual acuity (R2 [ 0.017; P [ .470) or central foveal thickness (R2 [ 0.040; P [ .263). CONCLUSIONS: Central choroidal thickness decreases after anti-VEGF therapy for DME after 6 months, but may not be associated with functional or anatomic outcomes in eyes with DME.

AB - PURPOSE: To determine the effect of anti-vascular endothelial growth factor (VEGF) therapy on choroidal thickness in eyes with diabetic macular edema (DME). DESIGN: Aretrospective, cohort analysis of 59 eyes from 59 patients with DME without prior anti-VEGF therapy. METHODS: Choroidal thickness was measured using semiautomated segmentation of enhanced depth imaging optical coherence tomography images at 0.5-mm intervals from 2.5 mm nasal to 2.5 mm temporal to the fovea. Changes in choroidal thickness with and without anti- VEGF treatment over 6 months were compared. Bestcorrected visual acuity and central foveal thickness were analyzed to evaluate the association of choroidal thickness with functional and anatomic outcomes. RESULTS: Of the 59 eyes with DME, 26 eyes were observed without treatment, whereas 33 underwent intravitreal anti-VEGF therapy (mean number of injections, 2.73) over 6 months. In untreated eyes, there was no significant change in best-corrected visual acuity (P [ .098), central foveal thickness (P [ .472), or choroidal thickness at all measurements along the macula (P[ .057 at the fovea). In eyes treated with anti-VEGF injections, choroidal thickness decreased significantly at the fovea (246.6 to 224.8 mm; P < .001) and at 0.5 mm nasal (240.9 to 221.9 mm; P [ .002) and 0.5 mm temporal (249.3 to 224.8 mm; P [ .011) to the fovea. The decrease in subfoveal choroidal thickness after anti-VEGF treatment was not associated with the cumulative number of anti-VEGF injections (R2 [ 0.031; P [ .327) or to changes in best-corrected visual acuity (R2 [ 0.017; P [ .470) or central foveal thickness (R2 [ 0.040; P [ .263). CONCLUSIONS: Central choroidal thickness decreases after anti-VEGF therapy for DME after 6 months, but may not be associated with functional or anatomic outcomes in eyes with DME.

UR - http://www.scopus.com/inward/record.url?scp=84908545376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908545376&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2014.06.006

DO - 10.1016/j.ajo.2014.06.006

M3 - Article

C2 - 24952275

AN - SCOPUS:84908545376

VL - 158

SP - 745-751.e2

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 4

ER -